Nephrogenic fibrosing dermopathy classification

Jump to navigation Jump to search

Nephrogenic fibrosing dermopathy Microchapters

Home

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Nephrogenic fibrosing dermopathy from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Nephrogenic fibrosing dermopathy classification On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Nephrogenic fibrosing dermopathy classification

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Nephrogenic fibrosing dermopathy classification

CDC on Nephrogenic fibrosing dermopathy classification

Nephrogenic fibrosing dermopathy classification in the news

Blogs on Nephrogenic fibrosing dermopathy classification

Directions to Hospitals Treating Nephrogenic fibrosing dermopathy

Risk calculators and risk factors for Nephrogenic fibrosing dermopathy classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Classification

The European authorities have classified the gadolinium-containing contrast agents in three groups:[1]

  • Least likely (safest) to release free gadolinium ions Gd3+ in the body have a cyclical structure: Dotarem, Gadovist and ProHance
  • Intermediate have a ionic linear structure: Magnevist, MultiHance, Primovist and Vasovist
  • Most likely to release Gd3+ have a linear non-ionic structure: Omniscan and OptiMARK

It can be noted that this classification was released after another proposition would have left the safest category (ionic cyclical structure) with only one agent (Dotarem). The intermediate category would have been either ionic linear structure or non-ionic cyclical structure. The third category most at risk was unchanged (linear non-ionic).[2]

References

Template:WH Template:WS